Eye cancer · Articles

Is Eye Cancer Curable? What the Evidence Shows for Each Type

Yes, many eye cancers are curable, and most can be controlled in the eye, especially when they are found early. The outlook depends on the type: in high-income countries, 99.5% of children with retinoblastoma are alive 3 years after diagnosis, and most eyelid cancers are cured by surgery. In the United States, about 84% of people with uveal melanoma are alive 5 years after diagnosis. In eye melanoma, the main risk is spread to other organs, which depends on the tumor's size and genetics.
Uveal melanoma, 5-year survival (US)
about 84%; 88% if confined to the eye
Retinoblastoma, 3-year survival
99.5% in high-income countries
Eyelid basal cell carcinoma
cured in up to about 98%
Tumor control in the eye after radiotherapy
about 95% in recent series
Most important factor
diagnosis while the tumor is small

When you hear the words "eye cancer," the first question is usually whether it can be cured. For many people, the answer is yes. Most eye cancers can be controlled in the eye, and many are cured, especially when they are found while still small. But "eye cancer" covers very different diseases, and each has its own outlook.

Is eye cancer curable? The outlook at a glance

Cancer Mainly affects What published figures show
Uveal melanoma (choroid, ciliary body) Adults About 84% alive at 5 years (US); 88% if confined to the eye
Iris melanoma Adults More than 95% alive at 5 years
Retinoblastoma Young children 99.5% alive at 3 years in high-income countries, 57.3% in low-income countries
Squamous growths of the eye surface (OSSN) Adults Usually curable; about 10% come back within a year of surgery
Conjunctival melanoma Adults About 83% have not died of melanoma at 5 years
Basal cell carcinoma of the eyelid Adults Cured in up to about 98% at 5 years
Conjunctival lymphoma, MALT type Older adults 97% have not died of lymphoma at 5 years

These figures describe large groups of patients. They cannot predict one person's outcome, which depends on the tumor's type, size, position and genetics.

What do "cure" and "control" mean?

  • Local control means the tumor in the eye has been destroyed or has stopped growing. After modern radiotherapy for uveal melanoma, this is achieved in about 95% of eyes.
  • Cure means the cancer is gone and does not come back anywhere in the body. Some cancers return years later, so results are usually given as survival at 5 or 10 years.
  • Remission, a word used mostly for lymphoma, means that no disease can be found after treatment.

These outcomes do not always go together. A melanoma can be controlled in the eye even if some cells spread before treatment began. For children with retinoblastoma, the goals come in a fixed order: first the child's life, then the eye, then as much vision as possible.

Can you survive uveal melanoma (eye melanoma)?

Yes, most people do. In the United States, about 84% of people with uveal melanoma are alive 5 years after diagnosis (American Cancer Society, cases from 2015–2021). The figure is 88% when the cancer is confined to the eye, 65% when it has reached nearby tissue and 19% when it has spread to distant organs.

Uveal melanoma: people alive 5 years after diagnosis (US)
  • Confined to the eye88%
  • Reached nearby tissue65%
  • Spread to distant organs19%

Treatment in the eye usually works. For medium-sized tumors, a large American study found the same survival after eye-sparing plaque brachytherapy as after removal of the eye. In brachytherapy, a small radioactive disc is sewn onto the eye for a few days. The main risk is spread through the blood (metastasis), most often to the liver. This happens in roughly a quarter of patients within 5 years and in about a third within 10.

The risk depends strongly on the tumor's thickness. Genetic tests on tumor cells refine the estimate (see genetic testing and biopsy):

What is measured Group Chance of spread within 5 years
Tumor thickness Up to 3 mm About 6%
Tumor thickness 3.1–8 mm About 14%
Tumor thickness More than 8 mm About 35%
Gene test (expression profile) Class 1A About 2%
Gene test (expression profile) Class 1B About 21%
Gene test (expression profile) Class 2 About 72%

Iris melanoma, at the front of the eye, has a much better outlook.

If melanoma spreads, treatment aims to keep it under control. Tebentafusp is a drug approved for people with the tissue type HLA-A*02:01, which can be identified with a blood test. In its phase 3 trial, it doubled 5-year survival compared with other treatments (16% versus 8%). See uveal melanoma prognosis and metastasis and follow-up.

Is retinoblastoma curable?

Yes, when it is diagnosed in time. Retinoblastoma, the main eye cancer of young children, is highly curable. A study of 4,064 children from 149 countries compared survival 3 years after diagnosis:

Country income level Children alive at 3 years
High 99.5%
Upper-middle 91.2%
Lower-middle 80.3%
Low 57.3%

The gap comes mostly from late diagnosis. In low-income countries, 42.9% of children already had cancer outside the eye when it was found, compared with 0.8% in high-income countries.

Many eyes are now saved with chemotherapy given into the eye's artery or into the eye, combined with laser and freezing treatment. An eye with very advanced disease may still need to be removed to protect the child's life.

Are cancers of the eye surface and eyelid curable?

Usually, yes, and they tend to be visible early.

  • OSSN (ocular surface squamous neoplasia) ranges from precancerous change to squamous cell cancer of the conjunctiva and cornea. It is usually curable with surgery or chemotherapy eye drops. In a large series, it came back in about 10% within a year of surgery and in 17–21% within 5 years. So follow-up lasts for years.
  • Conjunctival melanoma behaves more like skin melanoma and can spread to the lymph nodes. In population data, about 83% of patients had not died of melanoma 5 years after diagnosis, and 69% at 10 years. It often comes back in the same place, so check-ups continue for life.
  • Basal cell carcinoma makes up 8–9 of every 10 eyelid cancers and almost never spreads. Complete removal, with the edges checked under the microscope, cures up to about 98% at 5 years. Rarer types need wider surgery and closer follow-up (see eyelid cancer).

Is lymphoma of the eye curable?

Lymphoma around the eye, in the conjunctiva, eyelid, orbit or tear gland, is usually a slow-growing type called MALT lymphoma (extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue). In a large series of conjunctival lymphomas, 97% of people with this type had not died of lymphoma 5 years later. Rarer, faster-growing types have a less favorable outlook.

Lymphoma inside the eye, vitreoretinal lymphoma, usually responds to treatment in the eye. But it is linked to lymphoma of the brain, which largely determines the outlook.

Why do early diagnosis and follow-up matter so much?

In almost every type of eye cancer, smaller tumors found earlier are easier to treat. The eye and sight are more likely to be saved, and such tumors spread less often. In uveal melanoma, the risk of spread rises with thickness. That is why a suspicious choroidal nevus, a "freckle" at the back of the eye, is photographed and measured regularly. In retinoblastoma, survival depends above all on how early the diagnosis is made.

Follow-up matters because some cancers come back late. After uveal melanoma, the 2026 guidelines of the US National Comprehensive Cancer Network (NCCN) advise liver scans for 5–10 years. Depending on risk, the scans range from every 3–6 months to once a year. The aim is to find any problem while it is still treatable.

How can you find out your own outlook?

Your own outlook depends on details that only an examination shows. Prof. Dr. Elif Betül Türkoğlu, an ophthalmologist and ocular oncologist in Antalya, Türkiye, examines adults and children with eye tumors and explains the findings. If you live elsewhere, you can first send your scans and reports for a remote second opinion.

Frequently asked questions

Can you survive eye cancer?

Yes, most people do. About 84% of people with uveal melanoma in the United States are alive 5 years after diagnosis. Most eyelid cancers are cured by surgery, and 99.5% of children with retinoblastoma in high-income countries are alive after 3 years. The outlook is worse when the diagnosis comes late or, in melanoma, when the cancer has spread to other organs.

Can the eye be saved?

Often, yes. Uveal melanoma is usually treated in a way that keeps the eye, such as plaque brachytherapy, and modern radiotherapy controls the tumor in about 95% of eyes. In retinoblastoma, many eyes are saved with chemotherapy into the eye's artery or into the eye, plus laser and freezing treatment. A very advanced tumor may still mean that the eye has to be removed.

Is eye cancer painful?

Usually not in its early stages. Most eye cancers are found because of blurred vision, a visible spot or a routine examination. Pain tends to come with advanced tumors or raised eye pressure, so do not wait for pain before seeing a doctor. The signs to watch for are listed in eye cancer symptoms.

Can uveal melanoma come back after treatment?

It can, in two ways. The tumor can regrow in the treated eye; this is uncommon after modern radiotherapy and can often be treated again. Or melanoma can appear in another organ, most often the liver, sometimes years later. Regular eye examinations and liver scans aim to find both early.

Does removal of the eye mean the cancer was more serious?

Not necessarily. For medium-sized uveal melanoma, survival is the same after eye-sparing radiotherapy and after removal of the eye. Removal is chosen when a tumor is very large, has damaged the eye or has not responded to other treatment. In those cases it can be the treatment that cures.

Is eye cancer hereditary?

Most eye cancers are not inherited. The main exception is retinoblastoma: a considerable share of cases is heritable, so brothers and sisters are examined (see retinoblastoma genetics). A few families with uveal melanoma carry an inherited change in the BAP1 gene. Genetic counseling helps when the family history suggests an inherited risk.

References

  1. American Cancer Society. [Eye cancer (uveal melanoma) survival rates, SEER 2015–2021]. cancer.org
  2. National Cancer Institute. [Intraocular (uveal) melanoma treatment, PDQ professional version]. cancer.gov
  3. EyeWiki (American Academy of Ophthalmology). Uveal Melanoma. eyewiki.org
  4. A Cure In Sight. [Gene expression profile classes in uveal melanoma]. acureinsight.org
  5. Piperno-Neumann et al. [Five-year survival with tebentafusp in metastatic uveal melanoma]. Annals of Oncology, 2026. sciencedirect.com
  6. [Plaque brachytherapy and proton therapy for uveal melanoma in 310 patients, Dublin]. 2026. pmc.ncbi.nlm.nih.gov
  7. Global Retinoblastoma Study Group. [Outcomes of 4,064 children in 149 countries]. Lancet Global Health, 2022. sciencedirect.com
  8. Shields CL, et al. [Conjunctival tumors in 5,002 cases]. Asia-Pacific Journal of Ophthalmology, 2017. journals.lww.com
  9. [Review of conjunctival melanoma: incidence, biology, treatment and outcomes]. Cancers (MDPI), 2024. mdpi.com
  10. EyeWiki (American Academy of Ophthalmology). Basal Cell Carcinoma. eyewiki.org
  11. Cleveland Clinic Consult QD. [2026 NCCN uveal melanoma guidelines: risk-based surveillance]. 2026. consultqd.clevelandclinic.org

Need an ocular oncology opinion?

Send your scans and reports for a review by Prof. Türkoğlu, or book a consultation in Antalya. Adults and children are seen.

Send a request